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Highlights 
 The present study offers potential for identifying biological correlates (dysregulated sleep and
melatonin onset) in adolescents who are at high risk for developing bipolar disorder due to a
positive family history.  While the current study involves a relatively small number of
participants, it is likely to spur larger studies to identify potentially vulnerable youth for this
disabling disorder.
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Abstract 
Melatonin secretion and polysomnography (PSG) were compared among a group of healthy 
adolescents who were at high familial risk for bipolar disorder (HR) and a second group at low 
familial risk (LR). Adolescent participants (n =12) were a mean age 14 ± 2.3 years and included 
8 females and 4 males. Saliva samples were collected under standardized condition light (red 
light) and following a 200 lux light exposure over two consecutive nights in a sleep laboratory.  
Red Light Melatonin onset (RLMO) was defined as saliva melatonin level exceeding the mean of 
the first 3 readings plus 2 standard deviations. Polysomnography was also completed during each 
night. HR youth, relative to LR, experienced a significantly earlier melatonin onset following 
200 lux light exposure. Polysomnography revealed that LR youth, relative to HR, spent 
significantly more time in combined stages 3 and 4 (deep sleep) following red light exposure. 
Additionally, regardless of the group status (HR or LR), there was no significant difference in 
Red Light Melatonin Onset recorded at home or in the laboratory, implying its feasibility and 
reliability. 
 
Key words: bipolar, risk, melatonin, polysomnography, adolescent 
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1. Introduction: 
Bipolar disorder (BP) is a serious and a disabling illness, associated with impairment in 
multiple domains of function.  A positive family history of BP in a first degree relative (parent or 
a sibling) is a major risk factor for the later development of BP (Gershon et al. 1982; Tsuang and 
Faraone 1990). The rate for BP is 8 -10% among children and adolescents who have one parent 
with BP, however, an overall increased rate of any type mood disorder is also observed in youth 
who have one parent with BP (5 to 67%), when compared with offspring of healthy controls (0 to 
38%) (DelBello and Geller 2001).  
A critically important challenge in clinical practice is to accurately identify children and 
adolescents who are currently symptom free but are at an elevated future risk due to their family 
history (Berk et al. 2007). It is believed that early detection and intervention among those at high 
risk for BP could be linked with the prevention of symptoms, reduced suicide risk, and improved 
course of illness, although studies are needed in this domain (Howes and Falkenberg 2011). 
These patients may show a range of non-specific symptoms including irritability, poor affect 
regulation, anxiety, depression, inattention, impulsivity, sleep disturbance, stubborn behaviors, 
unstable self-esteem, or rejection sensitivity (Chang et al. 2000; Shaw et al. 2005; Jones et al. 
2006; Duffy et al. 2010).  Disturbed sleep or anxiety may emerge as early as 3 years of age in 
those at familial risk for BP (Faedda et al. 2004). In fact, several studies have attempted to 
identify sleep and/or circadian disturbances in children at familial risk, using a variety of 
techniques such as sleep diaries, actigraphy, melatonin secretion and polysomnography (PSG).  
Results have varied depending on the technique used.  For instance, using actigraphy in children 
of BP parents and controls, one study found greater subjective disturbance of sleep in children of 
BP parents (Jones et al. 2006). Ritter et al (2012) found that the sleep of high risk young adults 
(mean age = 25 years) was more analogous to the sleep of BP patients, with both groups 
experiencing recurring episodes of insomnia or hypersomnia, difficulty in being able to shift 
circadian rhythms, difficulty in awakening, and episodes of prolonged sleep (Ritter et al. 2012).   
 Our interest in melatonin secretion and the effect of light in youth at risk for BP is based 
on published literature involving high risk young adults, euthymic adults with BPI, adult bipolar 
patients or those with other types of cyclical mood disorders and animal data. Specifically, the 
data show that  i) melatonin is consistently reported as a reliable marker of circadian rhythms 
(Lewy 1983); ii) adolescents and young adults with no personal history of a major affective 
disorder but with parental BP (in one or both parents) were found to have a supersensitive 
suppressant response to light, suggesting that this may be a trait marker for BP (Nurnberger et al. 
1988); iii) in medication-free euthymic BP 1 adults, melatonin levels following exposure to light 
fall twice as much compared to controls, underscoring the possibility that melatonin is a trait 
marker for BP (Lewy et al. 1985; Nurnberger et al. 2000); iv) acutely ill BP patients were noted 
to have lower baseline melatonin levels (Lam et al. 1990); v) involvement of melatonin has been 
postulated in cyclical mood disorders such as BP, cyclothymia and seasonal affective disorders 
(Pandi-Perumal et al. 2007); and vi) animal data provide additional support for the role of light in 
the pathophysiology of mood disorders (LeGates et al. 2012).  LeGates et al (2012) had found 
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that mice exposed to aberrant light cycles displayed increased depression-like behaviors and 
impaired learning (LeGates et al. 2012).  Based on these observations, we hypothesized that 
melatonin secretion under dark and light conditions would significantly differ between 
adolescents at familial risk for BP, when compared to controls without a family history.  We 
further hypothesized that salivary melatonin could be reliably measured at home in both 
participant groups.   
 Hormones most closely aligned with circadian rhythms, such as cortisol, melatonin or 
thyroid hormones have not been adequately studied in children and adolescents at familial risk. 
In humans, circadian rhythms are controlled by a “biological clock” in the suprachiasmatic 
nucleus (SCN), which is located in the anterior portion of the hypothalamus close to the optic 
nerve.  The SCN is regulated by internal and external factors.  Among external factors, also 
known as zeitgebers, light is one the most powerful influences. Abnormalities in circadian 
rhythms can include damped amplitude, a phase advance or delay, or a non 24 period (McClung 
2007). These concepts apply to all measures of circadian rhythms, including the rest activity 
cycles, Red Light Melatonin Onset (RLMO) and melatonin secretion in response to a light 
exposure (LE). 
The overall aims of the present study are to compare the effect of light on secretion of 
melatonin and polysomnography between high risk (HR) and low risk (LR) adolescents. HR 
adolescents were at an elevated risk for BP due to a positive family history of BP in a first degree 
relative (parent or a sibling). We chose to study melatonin secretion and sleep because these are 
objective phenomena that can be studied with little or no subjective input from adolescents. 
Melatonin can be collected in youth in clinical practice and research, albeit with some training of 
the participants for accurately completing a timed-procedure.  We also aimed to demonstrate that 
Red Light Melatonin Onset could be reliably measured in the home setting, in both groups, 
which could significantly reduce the cost of the procedure.  
2. Methods 
The investigators obtained IRB approval at the University of Michigan, Ann Arbor where this 
study was conducted.  
2.1. Subjects 
Participants were 14 youth (data are reported for 12) comprised of 10 females and 4 males (7 HR 
and 7 LR) ranging in age from 12 to 18 years. Subjects were recruited via flyers, advertisements 
and child and adolescent psychiatry clinics at the University of Michigan, Ann Arbor. 
Participants were matched on age and gender but not on pubertal status and none were related to 
each other.  A positive history of BP in a parent was determined based on history (from the 
parent), who had completed a Family Mental History form, and any other records provided by 
the parents. All HR participants had one parent with a positive history of BP, although one HR 
participant had both a parent and a sibling with the disorder.  Presence of another mood disorder 
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 6 
in first degree relatives, in addition to BP, was not an exclusion. 
Exclusion criteria for all participants were DSM-IV diagnoses of BP, MDD, schizoaffective 
disorder, schizophrenia or substance abuse/dependence disorders; intellectual disability based on 
educational history; a significant medical or neurological disorder; and/or a history of taking any 
psychotropic medication during the previous week (3 weeks for fluoxetine) including 
antidepressants, antipsychotics, benzodiazepines, stimulant medication and/ or a non-stimulant 
agent for ADHD or a mood stabilizer. 
Reported numbers vary based on participants who completed a particular procedure and/or based 
on the requirements of a given analysis (for instance, melatonin level > 3 pg/ml was not achieved 
by all participants). One subject was lost to contact prior to participation and one subject was 
missing some, but not all data (equipment malfunction when acquiring PSG and no saliva 
collected for LE).  The total that completed all study procedures were 8 females (HR = 4) and 4 
males (HR = 2), while partial data were available for one subject (belonged to LR group).   
2.2. Procedures 
Both subject groups participated in the collection of Red Light Melatonin onset (DLMO), 
melatonin secretion following 200 lux white light exposure (LE) over two hours, and 
polysomnography. These procedures were completed in the UM Sleep Laboratory over two 
consecutive nights.  Standard red light melatonin onset protocol, described below, followed by 
sleep polysomnography and the light challenge night which included exposure to 200 lux light 
(during the first two hours of saliva collection) were completed by HR and LR groups. The order 
of the light challenge night was randomized.  In the home setting, saliva collection under Red 
Light condition was limited to one night, was completed under identical conditions to Red Light 
Melatonin Onset in the laboratory and was completed by both groups.  
The following standardized interviews and scales were completed at study-entry:  
1. K-SADS-PL (Kiddie – Schedule for Affective Disorder and Schizophrenia – Present) 
(Kaufman et al. 1997): The screening portion of this semi-structured diagnostic interview was 
completed which is designed to assess current and past episodes of psychopathology in children 
and adolescents. 
2. SCARED (Screen for Child Anxiety Related Emotional Disorders) (Birmaher et al. 1999): 
This is a child self-report instrument used to screen for childhood anxiety disorders. 
3. CDI (Children’s Depression Inventory) (Kovacs 1985):  The participant completes this 
symptom-oriented scale to measure the severity of depressive symptoms. 
4. CBQ-Adolescent (Conflict Behavior Questionnaire-Adolescent) (Robin and Foster 1989): 
This instrument is completed by the youth and is designed to assess the emotional quality of their 
interaction with each parent.  
6. SEI (Self Esteem Index) (Brown and Alexander 1991): This is a self-completed instrument 
which measures self-perception and self-worth of the youth. 
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7. HSS (Harter’s Social Support Scale, Child) (Harter 1985): This scale has four different 
subscales including Parent Subscale, Classmate Subscale, Close Friend Subscale, and a Teacher 
Subscale. 
8. FACES II (Family Adaptability and Cohesive Evaluation Scales) (Olson et al. 1991): This is 
a self-completed scale that determines how frequently a family participates in activities that are 
found to build cohesion and adaptability.   
 
2.3. Procedures during Red Light Melatonin Onset (RLMO) 
 Based on their normal sleep patterns, for 5-7 days prior to their scheduled in-lab procedures, 
subjects kept sleep diaries and wore an actigraphy watch during the week prior to sleep study to 
verify adherence to the schedule. They were advised that a deviation in their bedtime or rise 
time, if greater than a half-hour, would result in exclusion from the study.  Subjects arrived 5 
hours before their scheduled bed-time to ensure adequate time to settle prior to the start of saliva 
collection and other procedures. For Red Light Melatonin Onset, they were given a pair of blue-
blocking, orange glasses upon their arrival and told to put them on. Though melatonin secretion 
is sensitive to light above 10 lux, the orange glasses block short wave length blue light (400-500 
nm) and provide a standardized environment (Middleton et al. 2002; Hanifin et al. 2006). The 
glasses also ensured that adolescents did not have to stay in very low light for the collection of 
Red Light Onset samples.   Beginning 4 hours prior to their scheduled bed-time, saliva samples 
(9 for each subject) were collected every 30 minutes using Salivette tubes (Sarstedt, USA). The 
last saliva sample was collected at their stated bedtime, therefore, subjects did not remain awake 
beyond their bedtime.  Based on this, in the statistical analyses, the bedtime was considered as 
the reference point, i.e. time “0”.   
Fifteen minutes prior to collection of each saliva specimen, subjects brushed their teeth without 
toothpaste and rinsed their mouth. Subjects were also asked to remain seated for 5 minutes prior 
to each collection period, to minimize postural effects (Crowley et al. 2006).  Each sample was 
collected by asking the subject to open the salivette tube into his or her mouth without touching 
the cotton and to roll the cotton around in their mouth for 2 minutes without chewing it. Then the 
subject was instructed to expectorate the cotton back into the salivette without touching it. They 
followed identical directions in the laboratory and their home, with the exception that during the 
laboratory collection, the staff assisted the subjects with timing themselves while they rolled the 
cotton in their mouth for 2 minutes. Samples were labeled, centrifuged within 2 hours of 
collection at 3000 rpm (only lab-collected samples were centrifuges within 2 hours; home-
collected samples were centrifuged the following day) for 10 minutes at room temperature and 
refrigerated at -20
o
 C prior to assay.  
 
2.4. Procedures for measuring melatonin secretion following exposure to 200 lux light (LE) 
Subjects underwent the LE protocol on one of two nights in the laboratory. Identical procedures 
described under Red Light Melatonin Onset were followed for the collection of saliva 4 hours 
prior to the subject’s bedtime. The only addition during the LE protocol was exposure to 200 lux 
light for 2 hours that was started at the beginning of the 4-hour saliva collection period (subjects 
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 8 
did not wear orange glasses during the light exposure). Standardization was achieved by 
instructing subjects to not look directly into the light source, watching a video of their choice 
during this two-hour light exposure and directing them to keep their eyes on the screen of a lap-
top computer placed several feet away to reduce the chance that they might look directly at the 
light. 
2.5. Procedure for home Red Light Melatonin Onset 
For home Red Light Melatonin Onset, subjects wore the orange-lensed glasses starting 4 hours 
prior to bedtime. The orange lenses attenuate the melatonin suppressing effects of light 
(Sasseville et al. 2006).  Salivary samples were collected every 30 min, following the same 
procedures as the laboratory Red Light Melatonin Onset, except that samples were labeled and 
refrigerated until they were collected by staff the following morning. Studies by Jensen et al. 
(2011) (Jensen et al. 2011) have shown the stability of salivary melatonin at room temperature.  
Based on this literature, we have conducted several experiments leaving salivary samples 
unrefrigerated for one week and freezing and thawing samples to demonstrate that melatonin 
assays would not be compromised during home collection.  
Melatonin was assayed at the University of Michigan Core Assay Facility in the Department of 
Psychology, following published procedures (Conroy et al. 2012), but with age-appropriate 
melatonin onset criteria (Crowley et al. 2006).  Samples containing 1 mL of saliva were assayed 
in duplicate for melatonin using a radioimmunoassay kit (American Laboratory Products, 
Windham, NH). The range of possible values is between .5 and 50 pg/mL. The sensitivity of the 
assay is 0.2 pg/mL, and the interassay variability ranges from 16% to 22% for a high 
concentration and from 1.7% to 2.4% for a low concentration.  
2.6. Polysomnography 
Polysomnography data were completed on both nights in the laboratory using a Vitaport III 
recording system, following standardized laboratory procedures. EEG was recorded from C3 and 
C4 electrodes, referenced to the earlobes and connected to a 10-k resistor to minimize 
nonhomogeneous current flow. The electrode montage also included left and right electro-
oculogram (EOG) leads placed on both the upper and the lower canthi; a bipolar, chin-cheek 
electromyography (EMG); leg leads, chest and abdomen respiration bands, and a nasal-oral 
thermistor. Impedances were maintained below 2 kOhms. The scoring of sleep was performed in 
accordance with the recommended standards and specification as outlined in the American 
Academy of sleep Medicine Manual (AASM) for the Scoring of sleep and Associated Events 2.0 
(Berry et al. 2012).  Scoring of respiratory events followed the AASM guidelines (Iber et al. 
2007). Using adult criteria, where apneas were defined as > 90% reduction in air flow of at least 
10 sec duration and hypopneas were defined as a 30% drop in flow of at least 10 sec duration, 
with ≥ four percent desaturation; none of the subjects in the present study had an apnea hypopnea 
index > 0. In fact, none of the participants showed respiratory events that lasted 20 seconds or 
longer and were associated with ≥ 3% desaturation. EEG arousal was defined as an abrupt shift 
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 9 
to higher frequency of > three seconds duration and preceded by > 10 seconds of stable sleep 
(Scholle et al. 2012).  
PSG variables included total sleep time, time in bed, sleep latency (to the first epoch of any sleep 
stage), REM latency, % N1 (Stage 1), N2 (Stage 2) and N3 (Stages 3+ 4), % REM, and wake 
time after sleep onset.  Sleep efficiency was computed as the % total sleep time relative to time 
in bed.  
2.7. Analyses 
SPSS was used to conduct statistical analysis. Statistical significance was set at p-values less 
than 0.05. Continuous variables (e.g. age) are presented as mean ± standard deviation while 
categorical variables (e.g. gender) are presented as frequencies. Independent sample t-tests were 
used to compare LR and HR groups with respect to continuous variables, while Chi-square (or 
Fisher exact tests if the count was less than 5 in at least one cell) were used to test for 
associations between the two groups for categorical variables.  
Generalized estimating equations (GEE) were used to compare the two groups with respect to 
melatonin onset. GEE models are an extension of generalized linear models in that they allow 
adjusting for correlations between observations (i.e. the correlation between melatonin onset 
under the red light and 200 lux light exposure for each participant) (Ziegler and Vens 2010). A 
GEE model was computed for each melatonin onset method, and the model included melatonin 
onset as the dependent variable and the risk group (HR compared to LR) and light condition (200 
Lux compared to red light) as independent variables. If either variable was found to be 
significant, an interaction variable (i.e. risk group x light condition) was added to the model.  
Similarly, two GEE models (one model for each melatonin onset method) were used to examine 
whether there was a difference between melatonin levels collected at home versus in the 
laboratory. Each model was conducted with melatonin onset as a dependent variable, location 
(home versus laboratory) as an independent variable and was then repeated while controlling for 
risk status (HR versus LR). 
Calculation of Melatonin onset in response to light exposure and Red Light Melatonin Onset was 
computed as follows: Red Light Melatonin Onset (RLMO) refers to the time when melatonin 
levels reach a certain threshold value, depending on the definition used. This was calculated 
using two different methods that are established in the literature and because there is a lack of 
consensus about the most optimum method (Lewy et al. 1999; Benloucif et al. 2005). The first 
method uses a 3 pg/mL as the threshold for salivary melatonin, while the second method is based 
on when the mean value derived from the first 3 samples exceeds 2 standard deviations 
(Voultsios et al. 1997; Conroy et al. 2012).  Since participants were instructed to self-identify 
their bedtime and start the saliva collection 4 hours prior, bedtime was used as the reference 
time-point for each and was designated as time “0”.  Melatonin onset (under light exposure) and 
Red Light Melatonin Onset were designated as the earliest time before each participant’s 
bedtime when they achieved the defined threshold level for melatonin. 
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For the analyses involving the PSG data, we excluded an outlier with an exceedingly short total 
sleep duration of 25 minutes and another subject who had data only for one night.  
3. Results 
There was no significant age difference between HR and LR groups (14.5 ± 2.4 vs. 14.5 ± 2.3, p-
value = 1.00). Comparison of standardized rating scales, which were completed only at baseline, 
revealed that  the HR subjects had significantly greater affective lability scores (11.7 ± 6.2 vs. 
5.3 ± 4.4, p = 0.04) and lower adaptability and cohesion scores on the Family Adaptability and 
Cohesion scale (80 ± 19.4 vs 101± 8.3, p = 04).  There were no significant differences on other 
standardized scales (Table 1).   
 
-Table 1 - 
 
3.1. Findings Related to Melatonin 
We examined melatonin secretion in three different ways.  First, we examined a simple peak 
level; second, the time when a 3 pg/mL peak was reached; and third, when the melatonin level 
was 2 standard deviations above the mean of the first 3 measurements (Mean + 2 SD) among LR 
and HR under red light or 200 Lux exposure.  See figures 1-4. 
There was no significant difference between the LR and HR groups with respect to peak 
melatonin level measured during 200 lux exposure (9.8 ± 6.1 vs. 8.7 ± 5.0, p-value = 0.95, 
Cohen d = 0.2) or red light exposure (12.5 ± 9.6 vs. 10.4 ± 5.4, p-value = 0.68, Cohen d = 0.3; 
Figure 1). Further, there was no significant difference between groups with respect to time of 
peak melatonin level measured at 200 lux exposure (p-value = 0.70), red light exposure (p-value 
= 0.70), or at home (p-value = 0.84).  
-Figure 1 here- 
 
Using generalized estimating equations and based on a threshold of 3 pg/ml, there was no 
between-group difference in melatonin onset (B = 21.5, p = 0.37); however, within-subjects, 
there was a delayed melatonin secretion onset (closer to bed time) following exposure to 200 
Lux as compared to the red light exposure (B= -34.42, p = 0.002) (Figure 2). When an 
interaction between bipolar risk status (HR vs. LR) and light exposure was added to the model, 
the interaction was not found to be significant (B = 12.06, p = 0.59) indicating that impact of 
light on melatonin was similar among the high risk and low risk groups.  
 
-Figure 2 here- 
 
On examining the computation that was based on calculating the mean of the first three 
melatonin values plus two standard-deviations (M+2SD’s), a significant between-group effect 
was found; HR subjects experienced earlier Red Light Melatonin Onset compared to LR (B = 
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47.9, p = 0.004; Figure 3a). However, there was no within-subject effect (i.e. no impact of light 
exposure, B= -9.5, p = 0.57; Figure 3b). When the interaction between bipolar risk status and 
light exposure was added, a significant difference (B= 62.4, p = 0.02) was found, which 
indicated that the illness-risk status conferred a greater difference in onset of melatonin secretion 
during the 200 Lux light compared to the red light exposure (Figure 3a).  
 
-Figures 3a and 3b here- 
 
 
There was no significant difference in peak melatonin levels measured under Red Light 
Melatonin Onset in laboratory (11.5 ± 7.7) and home (11.6 ± 9.8; mean of difference ± SD= 0.2 
± 7.7, p = 0.91, Cohen D= 0.03).  Similar results were noted when the two groups were 
considered separately: (12.5 ± 9.6 vs. 13.3 ± 11.0, mean of difference ± SD= 1.0 ± 9.4, p = 0.78, 
n = 7 for LR group; 10.4 ± 5.5 vs. 9.7 ± 8.9, mean of difference ± SD = 0.6 ± 5.9, p = 0.80, n = 
6) at each setting (Figures 4a and 4b). There was no also impact of setting (i.e. home vs. lab) on 
Red Light Melatonin Onset whether it was calculated based on a threshold of 3 pg/ml (mean 
difference ± SD= 8.9 ± 39.6, p = 0.2, Cohen D= 1.4) or on M+2SD derived from the first three 
melatonin measurements (mean difference ± SD= 5.4±57.1, p = 0.76, Cohen D= 0.1). 
 
                                               -Figure 4a and 4b here- 
 
  
 
3.2. Findings Related to Polysomnography 
The LR group had a significantly higher percentage of N3 sleep (Stages 3 + 4 sleep) on the Red 
Light Melatonin Onset night compared with HR (26.2 ± 1.1 vs. 18.7 ± 5.5, p < 0.05). LR group 
also spent significantly longer wake time after sleep onset (41.2 ± 6.4 vs. 11.3 ± 8.1, p < 0.05) 
There were no significant differences in other sleep PSG measures. On the 200-lux light 
exposure night, there was a trend for a longer REM latency and a lower REM percentage among 
the HR group (Table 2). 
 
-Insert Table 2 here- 
 
 
4. Discussion 
Findings of the present study include: (1) HR participants experienced significantly earlier 
melatonin onset in comparison to LR controls following 200 lux light exposure (defining 
melatonin onset as the point at which melatonin reaches two standard deviations above the mean 
of the first three readings); however, there were no significant between-group differences when 
using a 3pg/ml level to define melatonin onset or when comparing peak melatonin levels ; (2) LR 
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youth, spent significantly more time in N3 sleep than the HR group on the Red Light Melatonin 
Onset night under standard red light condition, and (3) there was no significant difference in Red 
Light Melatonin Onset under the standard red light condition recorded at home or in the lab 
setting, regardless of the risk status of the groups (HR or LR). We also found that the LR group 
had a longer time awake after sleep onset under the red light condition.  Our overall findings 
indicate that there are identifiable circadian rhythm changes in asymptomatic adolescents who 
are at familial risk for BP.  We must acknowledge that our finding of an earlier melatonin onset 
among the HR group under the 200 lux exposure is in direction which is opposite of that reported 
by Nurnberger et al. 1988, where the participants were similar, although older, when compared 
to the participants included in the present study.  Below, we attempt to explain our findings on 
the basis of study design differences, while recognizing that the exact long-term implication of 
our findings is currently unknown, and there may be additional biological reasons pertaining to 
our findings which are beyond the scope of this study. 
There is a paucity of literature in regards with melatonin secretion under light conditions and/ or 
Red Light Melatonin Onset in individuals at risk for BP. Although, it is notable that young 
adolescents such as those included in the present study have not been previously studied. 
Furthermore, meaningful comparisons are difficult because of somewhat inconsistent findings in 
the published literature and study-design differences. Nevertheless, the overall findings indicate 
that melatonin dysregulation is associated both with HR status and with a BP clinical diagnosis.  
For instance, in one of the earliest studies among this sparse literature, Nurnberger et al (1988) 
studied HR youth (age range = 15 to 25 years, mean age of participants with one BP parent = 
20.5 years; subjects with one manic-depressive parent = 18, major affective disorder on both 
sides of the family = 7, controls = 20); HR, relative to controls, were more sensitive to a 
melatonin-suppressant effect of 500 lux light exposure between 1 and 2 AM (Nurnberger et al. 
1988). In another study, Nurnberger and colleagues (2000) studied euthymic adults with BP (n = 
29), unipolar disorder (n = 25) and controls (n = 50). No group differences were detected 
following a 500 lux light exposure between 2 and 4 AM.  However, euthymic BP adults, relative 
to controls, had a lower baseline and peak melatonin levels on the night of light exposure, and 
the peak was noted to occur later on in the night when they were exposed to red light 
(Nurnberger et al. 2000). In one other study involving adults with BP (n = 8), unipolar disorder 
(n = 7) or controls (n =15), Lam et. al. (1990), in response to 500 lux exposure from 1 AM to 
2.15 AM, found greater nocturnal melatonin suppression among controls relative to BP who 
were experiencing an acute illness episode; however, BP had a lower baseline melatonin while 
unipolar participants did not differ from controls (Lam et al. 1990). In contrast to the 
aforementioned studies, Whalley and colleagues (1991) failed to identify a differential melatonin 
suppressant effect of 500 lux light exposure between 2 and 4 AM administered to medication-
free euthymic adults with BP disorder and controls (n = 15 in each group); in that study, both 
groups experienced similar melatonin suppression following the light exposure (Whalley et al. 
1991).  We should note that the timing of the light exposure among these previously published 
studies was considerably different from the present study. Therefore, comparisons are difficult 
given that the timing of the light exposure has been shown to exert an important influence on 
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melatonin secretion (Lewy 1983; Lewy et al. 1985; McIntyre et al. 1989). 
An additional important design difference which makes it difficult to compare present findings 
with the previous literature are the participant related differences. The present study is notable 
for younger participants; subjects lacked a psychiatric diagnosis at the time of their participation; 
we measured melatonin onset versus melatonin secretion; and unlike the previous studies, we 
utilized a lower-intensity light exposure, which was standardized using the bedtime of each 
participant.  We note that unlike previous studies, we found earlier melatonin onset in HR 
subjects following exposure to light; this finding is in direction that is opposite to what has been 
reported in the past.  
Based on our findings and in context of the past work, we hypothesize that various different 
phases of bipolar disorder (high risk status, acute illness and euthymic states during a confirmed 
diagnosis) may be associated with subtle, yet variable melatonin secretion patterns.  Thus, 
dysregulated patterns of melatonin secretion may be both a trait and a state marker for the illness. 
Only larger studies, which include carefully, defined subjects and standardized light and dark 
protocols can provide confirmatory evidence. 
In regard to the PSG/ sleep related finding in the present study, we identified that the LR group, 
relative to HR, had significantly higher percentage of combined Stages 3 and 4 (N3), but only 
following the red light exposure. Unexpectedly, we also found longer awake time after sleep 
onset among LR under the red light condition. However, the higher N3 in LR is not accompanied 
by other sleep measures that would indicate more efficient sleep.  Importantly, findings of the 
present study should be considered preliminary and require replication in a larger sample to 
understand these in context of other reported PSG disturbances in this subgroup. Specifically, 
past findings have included fragmented sleep in adolescents diagnosed with BP (Mullin et al. 
2011), recurring insomnia and hypersomnia along with prolonged sleep latency among HR 
adolescents (Ritter et al. 2012), and longer stage 1 but diminished stage 4 among adolescents 
who later developed BP upon longitudinal follow up (Rao et al. 2002).  We speculate that the 
shorter N3 in HR could be a marker of more widespread sleep disturbances during full-blown 
mood episodes, while only a larger sample size may detect additional previously reported 
deficits.  
Although home Red Light Melatonin Onset is thought to be less expensive, there is scant 
evidence to support whether Red Light Melatonin Onset measured in the home is reliable with 
laboratory measurements.  One previous study involving healthy adults ranging in age from 21 to 
62 years found that Red Light Melatonin Onset assessed in the home of the participants was 
significantly correlated with Red Light Melatonin Onset completed in the laboratory (Burgess et 
al. 2015). Therefore, our finding regarding the high correlation between home and laboratory 
based Red Light Melatonin Onset in HR and LR adolescents replicates the findings of Burgess et 
al. (2015) and implies its feasibility and reliability.  
It must be noted that we chose to present the data prior to correction for multiple testing (though 
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correction is added as a footnote to table 2), for two reasons: firstly, there is an inherent difficulty 
in defining the number of independent tests for a fair correction to be applied; and secondly, due 
to the preliminary nature of the study, reporting of all suggestive findings will be more 
informative for future larger studies in defining specific variables for targeted analysis.  
Additional study limitations include: i) reliance on history to determine BP illness in first-degree 
relatives (instead of completing a diagnostic interview); ii) participants were matched on age and 
gender but were not matched on pubertal status, menstrual phase or season; iii) we do not report 
the participant’s bedtime-schedules and actigraphy prior to salivary melatonin collection; iv) the 
peak melatonin levels only reflect the highest level achieved during the 4 hour saliva collection 
period and are not based on the entire night; v) we did not control for ambient light; vi) the study 
is underpowered to check for interactions and, vii) due to the cross sectional nature of the study 
design, we do not yet know the longitudinal predictive value of these findings.  Additionally, we 
acknowledge that it is beyond the scope of this paper to discuss the mechanisms underlying the 
association between melatonin and BP 
While it may be premature to draw definite conclusions, our findings indicate that Red Light 
Melatonin Onset and melatonin secretion following a 200-lux light exposure may be relatively 
inexpensive tools, which could be used either alone or along with the more expensive laboratory-
based PSG, for characterizing the circadian rhythms of HR youth.  Our findings indicate that the 
HR group, relative to the LR, displayed a greater disruption in melatonin secretion and in their 
sleep pattern. Red Light Melatonin Onset, using the red light condition, could be reliably utilized 
in either subject-group in the home setting, which addresses important feasibility issues, which 
have thus far limited the scale of similar studies. The implications of these findings can only be 
clarified by larger studies, which should ideally include longitudinal outcomes.  Any reliable, 
inexpensive test with potential for predicting outcome could open the possibility for developing 
and implementing prevention strategies, which may improve outcome; this continues to be the 
overarching goal of this research.    
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Table 1: Clinical Factors among Low versus High Risk Groups 
 
Low Risk Group 
Mean ± SD 
High Risk Group 
Mean ± SD p-value 
Age 14.5 ± 2.3 14.5 ± 2.4 1.00 
Gender (Female) N=6; (75%) N=4; (66.7%) 1.00 
Children Affective Lability Scale 5.3 ± 4.4 11.7 ± 6.2 0.04* 
Children’s Behavior Questionnaire - 
Father 2.4 ± 3.7 3.8 ± 3.8 0.48 
Children’s Behavior Questionnaire - 
Mother  1.1 ± 1.6 1.8 ± 1.3 0.39 
Children’s Depression Inventory 25.3 ± 1.8 23.3 ± 2.3 0.10 
Screen for Child Anxiety Related 
Disorders (SCARED) 12.4 ± 8 15.2 ± 9.0 0.57 
Family Adaptability & Cohesion Scale           101 ± 8.3          80 ± 19.4              0.04* 
Harter Social Support Scale            3.5 ± 0.4          3.2 ± 0.3 0.28 
Self Esteem Index            390.4 ± 337        249.3 ± 31.3 0.33 
p < 0.05* 
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Table 2: Polysomnography Data 
 
Red light Night 200 Lux Exposure Night 
Group 
Low Risk 
Group 
n = 3 
Mean ± SD 
High Risk 
Group 
n = 6 
Mean ± SD 
p-
valu
e
1 
Cohe
n D 
Low Risk 
Group 
n = 4 
Mean ± SD 
High Risk 
Group 
n = 3 
Mean ± SD 
p-
value
1 
Coh
en 
D 
Total 
Sleep 
Time 452 ± 93.9
2
 488.2 ± 53.9 
0.7
1 0.5 473 ± 39.2 462.3 ± 28.3 0.63 
0.3 
Sleep 
Latenc
y 13.7 ± 16.2 13.5 ± 10.7 
1.0
0 0.3 14.9 ± 8.3 12.5 ± 4.0 0.63 
0.4 
Sleep 
Efficie
ncy
3
 86.7 ± 6.5 84.7 ± 24.3 
0.3
8 0.7 90.5 ± 5.9 92.4 ± 5.5 1.00 
0.3 
REM 
latency 
132.0 ± 
60.2 123.3 ± 45.2 
0.9
0 0.2 
103.9 ± 
41.3 171.2 ± 12.8 0.06 
2.0 
% 
REM 23.7 ± 5.1 23.4 ± 3.9 
1.0
0 0.9 27 ± 3.5 20.1 ± 5.7 0.06 
1.5 
% N1 
6.3 ± 1.6 6.3 ± 4.1 
0.9
0 0.1 6.4 ± 3.1 8.3 ± 1.6 0.40 
0.7 
% N2 
43.8 ± 7.3 51.6 ± 6.6 
0.1
7 1.2 46.8 ± 6.5 36.9 ± 27.1 1.00 
0.6 
% N3 
(Stage 
3+4) 26.2 ± 1.1 18.7 ± 5.5 
0.0
2
4 
1.6 19.8 ± 4.3 17.5 ± 7.4 0.63 
0.4 
Wake 
time 
after 
sleep 
onset 41.2 ± 6.4 11.3 ± 8.1 
0.0
2
4 
1.0 36.6 ± 40.4 39.7 ± 28.8 1.00 
0.1 
1 
p-value calculated using non parametric test 
2 
Excluding a subject with technical problems, and another outlier subject with total sleep time of 
25 minutes. When including the subject with technical problems, the mean total sleep time for 
lower risk group = 317.8 ± 205.8; p-value 0.18 
3 
Total sleep time/time in bed 
4 
Not significant after performing Bonferroni’s correction for multiple comparisons (i.e. 
comparing to 0.05/9 = 0.0056). 
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Figure 1: Peak Melatonin Level (pg/ml) by light exposure 
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Figure 3: Melatonin Onset Following Red and 200 Lux Light Exposure (cutoff > M+2SD) 
 
a)Each Setting stratified by risk group 
 
 
 
 
 
b) Each Risk group stratified by setting. 
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Figure 4: Melatonin Onset in Laboratory Compared to Home;using different cutoff points 
a) threshold of 3 pg/ml 
 
 
 
 
b) threshold of M+2SD 
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